Acclaim for Tushar Chande’s revolutionary approach for developing and implementing your own winning trading system

"Tushar Chande provides insightful but clear-cut techniques which will enlighten the savant as well as the newcomer. I would urge traders of all levels of experience to apply Chande's tremendously useful strategies!"–Charles Le Beau, President, Island View Financial Group Inc., author, Computer Analysis of the Futures Market

"The chapter on ‘Equity Curve Analysis’ alone will share with you concepts which have cost large trading houses millions of dollars to discover."–Murray A. Ruggiero Jr., Contributing Editor, Futures magazine

President, Ruggiero Associates

"Tushar Chande is an accomplished quantitative technician, but in this book he’s gone far beyond grinding numbers. His coverage of system development is the first thorough treatment disclosing both specific trading systems and the practicalities of their implementation."–John Sweeney, Technical Editor, Technical Analysis of Stocks & Commodities magazine; author, Maximum Adverse Excursion: Analyzing Price Fluctuations for Trading Management

"For any aspiring CTA, this is a must-read on developing [his or her] trading system."–Rick Leesley, Jack Carl Futures

The biotechnology business in India with an increase from USD 500 million in 1997 and reaching an estimated USD 1 billion next year health related prod ucts accounting for 60%, agro and veterinary products together 15%, and con tract R&D, reagents, devices and supplies adding up to the remaining 25% of which the diagnostics share was about 10% of the total surely presented an encouraging picture even five years ago. While volumes have increased, the pat tern has not. According to a report, prepared by McKinsey & Co, India's Phar maceutical industry including domestic and export sales and contract services totals nearly USD 5 billion. Furthermore, the company optimistically projects the growth to a factor of five fold only if both the industry and the government are able to put in place achievable solutions that must take care of the formida ble obstacles preventing further growth. If this assessment is correct, then the established transformation made by IT growth should also provide the confi dence required by the high expectations for biotechnology which have arisen in the country in recent years. Some contributors to this are overenthusiastic these are bureaucrats, some retired scientists and of course the complacent politicians who have the least knowledge of what the new biotechnology is all about. However, there are clear indications of biotechnology growth demon strated by a few but rapidly expanding biotech companies such as Biocon Ltd, Shantha Biotech (P) Ltd, Dr.

Advances in Comparative and Environmental Physiology helps biologists, physiologists, and biochemists keep track of the extensive literature in the field. Providing comprehensive, integrated reviews and sound, critical, and provocative summaries, this series is a "must" for all active researchers in environmental and comparative physiology.

The biotechnology business in India with an increase from USD 500 million in 1997 and reaching an estimated USD 1 billion next year health related prod ucts accounting for 60%, agro and veterinary products together 15%, and con tract R&D, reagents, devices and supplies adding up to the remaining 25% of which the diagnostics share was about 10% of the total surely presented an encouraging picture even five years ago. While volumes have increased, the pat tern has not. According to a report, prepared by McKinsey & Co, India's Phar maceutical industry including domestic and export sales and contract services totals nearly USD 5 billion. Furthermore, the company optimistically projects the growth to a factor of five fold only if both the industry and the government are able to put in place achievable solutions that must take care of the formida ble obstacles preventing further growth. If this assessment is correct, then the established transformation made by IT growth should also provide the confi dence required by the high expectations for biotechnology which have arisen in the country in recent years. Some contributors to this are overenthusiastic these are bureaucrats, some retired scientists and of course the complacent politicians who have the least knowledge of what the new biotechnology is all about. However, there are clear indications of biotechnology growth demon strated by a few but rapidly expanding biotech companies such as Biocon Ltd, Shantha Biotech (P) Ltd, Dr.